HRAS and cancer: The KRAS degrader specifically reduced proliferation of cells with mutant KRAS expression in 2D-adherent and 3D spheroid assays (Fig. 6a–c) but did not modify the proliferation of cancer cell lines with mutant NRAS or HRAS (Fig. 6d–f) nor of the RASWT cells HCC827 and MRC5 (Fig. 6g, h).